Trends & Analysis

Australia’s drug discovery industry shows promise and innovation, as well as business opportunities. DDW’s Megan Thomas takes a look at some of the reasons why we should be keeping an interested eye on the developments coming out of this country.   The Sector Snapshot 2022: Expansion is continuous   The Sector Snapshot 2022 was commissioned by AusBiotech, […]

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the International Trade Administration described as […]

Following a decade of solid groundwork to modernise regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape – to transform process management; improve data exchange with the enterprise at large; revisit organisational structures and roles, and enable greater patient access to information. […]

Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need.  Although cytomegalovirus (CMV) is almost ubiquitous in the adult population globally, it is an under-recognised infectious cause of […]

Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery.  Artificial intelligence (AI) is notorious for its industry hype, touted to revolutionise the way multiple sectors operate over the next five to 10 years. Its application in pharma, most commonly in drug discovery, […]

This paid-for advertorial by Benchling appeared in the DDW ebook – AI in drug discovery: How technology is driving innovation. By Ashoka Rajendra, Head of Development & Manufacturing Products at Benchling Artificial Intelligence (AI) is emblematic of the new era of modern biotech — data-driven, collaborative and ultimately, faster than ever. From discovery, to lead […]

DDW Editor Reece Armstrong explores how AI is being utilised in the lab and what the technology can really do within pharma.  Artificial intelligence (AI), a branch of computer science encompassing machine learning and deep learning, and which technologies such as automation, natural language processing (NLP) and image recognition all fall into, offers significant opportunity […]

The concept of Artificial Intelligence (AI) never fails to stimulate and in drug discovery the possibilities it presents, the potential it holds, are always thought-provoking, says DDW Publishing Director Lu Rahman.  The simulation of human intelligence processes by machines finds itself at an exciting moment for use within the drug discovery industry, especially as the […]

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year.   There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. This area of medicine, which turns our own bodies into […]

This paid-for advertorial by Bio-Rad appeared in the DDW ebook – Innovating in the lab: an essential guide to drug discovery technology. In the following article Richard J Cuthbert, PhD, Global Commercialisation Product Manager, Flow and Antibodies, Bio-Rad Laboratories examines the rise of flow cytometry as a screening tool. In recent years, the use of flow cytometry in drug […]